A practical reference on alpha-MSH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
== Description == Small clump-forming from a robust, somewhat woody rootstock with erect, hispid, unbranched stems 25–40 cm (9.8–15.7 in) high. Basal leaves linear elliptic to narrowly lanceolate, 10–15 cm (3.9–5.9 in) long with stalks to 4 cm (1.6 in); stem leaves smaller and sessile, velvety-hairy. Flowers are yellow, 3.5–4.5 cm (1.4–1.8 in) long by 1.2–1.6 cm (0.5–0.6 in) across densely planted on the ends of stems and branches. It flowers from early to late summer. All aerial parts are pubescent.
Methionine synthase reductase, also known as MSR, is an enzyme in humans that is encoded by the M1T3R gene. It functions as the obligate reductase for methionine synthase and restores its cofactor to an active state allowing it to sustain folate and methionine metabolosis.
Protein production is the biotechnological process of generating a specific protein. It is typically achieved by the manipulation of gene expression in an organism such that it expresses large amounts of a recombinant gene. This includes the transcription of the recombinant DNA to messenger RNA (mRNA), the translation of mRNA into polypeptide chains, which are ultimately folded into functional proteins and may be targeted to specific subcellular or extracellular locations. Protein production systems (also known as expression systems) are used in the life sciences, biotechnology, and medicine. Molecular biology research uses numerous proteins and enzymes, many of which are from expression systems; particularly DNA polymerase for PCR, reverse transcriptase for RNA analysis, restriction endonucleases for cloning, and to make proteins that are screened in drug discovery as biological targets or as potential drugs themselves. There are also significant applications for expression systems in industrial fermentation, notably the production of biopharmaceuticals such as human insulin to treat diabetes, and to manufacture enzymes.
WHO recommends assigning hazard classes to all MNMs according to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals for use in safety data sheets. For a limited number of MNMs this information is made available in the guidelines (strong recommendation, moderate-quality evidence). WHO recommends updating safety data sheets with MNM-specific hazard information or indicating which toxicological end-points did not have adequate testing available (strong recommendation, moderate-quality evidence). For the respirable fibres and granular biopersistent particles' groups, the GDG suggests using the available classification of MNMs for provisional classification of nanomaterials of the same group (conditional recommendation, low-quality evidence). B. Assess exposure to MNMs
== X == Xiaoliang Sunney Xie (born 1962), Chinese-American biochemist, pioneer in the field of Single Molecule Microscopy and CARS (Coherent Anti-Stokes Raman Spectroscopy) microscopy Xie Yi (born 1967), Chinese chemist, member of the Chinese Academy of Sciences and a fellow of the Royal Society of Chemistry.
Sources: en.wikipedia.org
=== Bipolar disorder === Lithium is primarily used as a maintenance drug in the treatment of bipolar disorder to stabilize mood and prevent manic episodes. It is also effective in the acute treatment of manic episodes. It is effective for mania within the first 7 days of treatment. For acute treatment, although recommended by treatment guidelines for the treatment of depression in bipolar disorder, the evidence that lithium is superior to placebo for acute bipolar depression is low-quality. Atypical antipsychotics are considered more effective for treating acute bipolar depressive episodes. Lithium is effective for the long term prevention of bipolar depressive episodes. Lithium treatment was previously considered to be unsuitable for children, however more recent studies show its effectiveness for treatment of early-onset bipolar disorder in children as young as eight. The required dosage is slightly less than the toxic level (representing a low therapeutic index), requiring close monitoring of blood levels of lithium during treatment. Within the therapeutic range there is a dose-response relationship. A limited amount of evidence suggests lithium carbonate may contribute to the treatment of substance use disorders for some people with bipolar disorder. People with bipolar disorder are at a 3 times higher risk for dementia. Lithium reduces the risk of dementia by 50% among people with bipolar disorder.
Clematis ispahanica Bioss Clematis × jackmanii T.Moore – Jackman's clematis Clematis koreana Kom. – Korean clematis Clematis lanuginosa Lindl. & Paxton Clematis lasiantha Nutt. – pipestem clematis Clematis leptophylla (F.Muell. ex Benth.) H.Eichler Clematis ligusticifolia Nutt. – western white clematis, hierba de chivo Clematis linearifolia Steud. Clematis macropetala Ledeb. – downy clematis Clematis mandshurica Clematis marmoraria Sneddon – New Zealand dwarf clematis Clematis microphylla DC. – small-leaved clematis Clematis montana Buch.-Ham. ex DC. – anemone clematis Clematis morefieldii Kral – Huntsville vasevine Clematis napaulensis DC. Clematis occidentalis (Hornem.) DC. – western blue virginsbower Clematis ochroleuca Ait. – curlyheads Clematis orientalis L. – Chinese clematis Clematis palmeri Rose – Palmer clematis Clematis paniculata J.F.Gmel. – puawhananga Clematis patens C.Morren & Decne. Clematis pauciflora Nutt. – ropevine clematis Clematis pickeringii A.Gray Clematis pitcheri Torr. & A.Gray – bluebill Clematis pubescens Hügel ex Endl. – common clematis Clematis recta L. – ground clematis Clematis reticulata Walter – netleaf leather flower Clematis rhodocarpa Rose Clematis smilacifolia Wall. Clematis socialis Kral – Alabama leather flower Clematis stans Siebold & Zucc. – kusabotan Clematis tangutica (Maxim.) Korsh. – golden clematis Clematis terniflora DC. – sweet autumn clematis Clematis texensis Buckley – scarlet leather flower Clematis urophylla Clematis versicolor – manycolored leather flower Clematis verticillaris – purple virgins bower Clematis viorna L.
=== Other senior wins (6) === 1987 Northville Invitational (United States), German PGA Team Championship 1997 Dai-ichi Seimei Cup (Japan) 2000 Senior Skins Game (U.S. – unofficial event) 2009 Liberty Mutual Legends of Golf – Demaret Division (with Bob Charles) 2010 Liberty Mutual Legends of Golf – Demaret Division (with Bob Charles) *The Senior British Open was retroactively recognised by the PGA Tour Champions as a senior major in 2018.
It is drained with each use and can be replenished by drinking from rats, visiting blood banks, or drinking from humans by attacking or seducing them; the player can feed on enemies during combat. Drinking from innocents for too long can kill them, costing a character humanity points. Players are penalized for using certain vampiric abilities in front of witnesses; exposing their existence loses masquerade points, although additional masquerade points can be earned from quests and other actions. Violating the masquerade five times draws the ire of vampire hunters and loses the game. The player has humanity points, representing the vampire's humanity. Some actions cost humanity points; a low humanity score alters available dialogue options to become more aggressive and increases the chance of entering a frenzied state and embarking on a killing spree when the vampire's blood is low. A large amount of damage can also trigger this frenzy. Like masquerade points, losing all humanity points ends the game, with the vampire becoming a mindless beast. Some areas, known as Elysium, prevent the use of Disciplines or weapons. Players can recruit a ghoul, Heather, as a customizable servant who gives them blood, gifts, and money.
== Function == The protein encoded by this gene is a member of the G protein-coupled receptor family 2. This protein is a receptor for parathyroid hormone (PTH) and parathyroid hormone 2 (PTH2). PTH2R is more selective in ligand recognition than the parathyroid hormone 1 receptor, and in particular is not activated by parathyroid hormone-related protein (PTHrP). It also has a more specific tissue distribution, and is particularly abundant in the brain and pancreas. The molecular interaction of PTH2R with the peptide PTH2 (previously TIP39) has been characterized in full 3D molecular detail, identifying among other residues Tyr-318 in transmembrane helix 5 as a key residue for high affinity binding.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.